-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31

Benzinga·05/11/2026 19:10:33
Listen to the news
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.